[BIO] Bio-Rad Laboratories, Inc.


Type of security: Stock

Sector: Capital Goods

Industry: Biotechnology: Laboratory Analytical Instruments

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 183.48 Change: 0.83 (0.45%)
Ext. hours: Change: 0 (0%)

chart BIO

Refresh chart

Strongest Trends Summary For BIO

BIO is in the long-term up 147% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test sy

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS2.61 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -11.92% Sales Growth - Q/Q-20.96% P/E84.52
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA3.01% ROE4.55% ROI3.44%
Current Ratio4.08 Quick Ratio2.93 Long Term Debt/Equity0.34 Debt Ratio0.19
Gross Margin54.87% Operating Margin7.66% Net Profit Margin4.68% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-330 K Cash From Investing Activities-27.99 M Cash From Operating Activities29.45 M Gross Profit270.11 M
Net Profit17.82 M Operating Profit34.35 M Total Assets3.33 B Total Current Assets1.7 B
Total Current Liabilities416.88 M Total Debt435.93 M Total Liabilities1.13 B Total Revenue472.82 M
Technical Data
High 52 week306.39 Low 52 week212.27 Last close306.39 Last change0.95%
RSI78.16 Average true range5.42 Beta0.7 Volume71.23 K
Simple moving average 20 days3.17% Simple moving average 50 days4.15% Simple moving average 200 days17.51%
Performance Data
Performance Week1.36% Performance Month2.17% Performance Quart16.83% Performance Half21.34%
Performance Year29.83% Performance Year-to-date28.37% Volatility daily1.16% Volatility weekly2.6%
Volatility monthly5.33% Volatility yearly18.46% Relative Volume236.57% Average Volume142.29 K
New High0.51% New Low


2019-04-17 11:54:03 | Abbott ABT Q1 Earnings Beat Estimates, Organic Sales Solid

2019-04-15 19:03:00 | Bio-Rad to Report First-Quarter 2019 Financial Results

2019-04-12 09:45:01 | Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks

2019-04-10 07:25:00 | FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year

2019-04-09 10:51:24 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.

2019-04-09 09:13:01 | Bio-Rad's BIO IH-500 System Secures 510K From the FDA

2019-04-09 07:30:54 | Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News

2019-04-09 00:10:54 | Dow Jones Futures: These 3 Stocks Are Big Movers Late On FDA News

2019-04-08 16:15:00 | Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market

2019-04-03 09:10:01 | Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm

2019-04-02 17:00:00 | Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer

2019-04-02 09:56:34 | Elon Musk’s CEO pay-to-worker ratio is the highest ever recorded — how it compares at other tech companies

2019-04-02 08:30:00 | Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay

2019-03-30 09:30:01 | Why Is Bio-Rad BIO Up 12.8% Since Last Earnings Report?

2019-03-27 07:25:00 | Recent Analysis Shows Transocean, Chipotle Mexican Grill, Marathon Oil, Laboratory Corporation of America, Bio-Rad Laboratories, and Graco Market Influences — Renewed Outlook, Key Drivers of Growth

2019-03-26 08:25:54 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.

2019-03-25 17:00:00 | Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing

2019-03-22 08:41:00 | GBT Reports Fourth Quarter and 2018 Results

2019-03-21 10:25:02 | Top Ranked Momentum Stocks to Buy for March 21st

2019-03-15 10:03:02 | Here's Why You Should Buy Masimo MASI Stock Right Now

2019-03-15 09:38:01 | Looking for a Growth Stock? Why It is Time to Focus on Bio-Rad BIO

2019-03-15 08:31:12 | BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost

2019-03-14 08:38:12 | Here's Why You Should Invest in Stryker SYK Stock Right Now

2019-03-14 08:36:12 | HEXO Catches Eye: Stock Jumps 6.6%

2019-03-12 08:45:12 | Here is Why Growth Investors Should Buy Bio-Rad BIO Now

2019-03-12 06:35:10 | Will Bio-Rad Laboratories Continue to Surge Higher?

2019-03-11 09:15:01 | Here's Why You Should Add Bio-Rad BIO to Your Portfolio

2019-03-06 10:12:03 | What Makes Bio-Rad BIO a New Strong Buy Stock

2019-03-05 07:30:00 | The $200K Club: Broadcom joins these Bay Area tech companies paying a typical employee top dollar

2019-03-01 08:50:54 | The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis

2019-03-01 07:51:12 | Bio-Rad BIO Earnings and Revenues Beat Estimates in Q4

2019-03-01 06:53:51 | Edited Transcript of BIO earnings conference call or presentation 28-Feb-19 10:00pm GMT

2019-02-28 16:38:00 | Bio-Rad Reports Fourth-Quarter and Full-Year 2018 Financial Results

2019-02-28 13:30:46 | Is Bio-Rad Laboratories, Inc. NYSE:BIO A Financially Strong Company?

2019-02-21 10:31:03 | Bio-Rad Laboratories BIO Reports Next Week: Wall Street Expects Earnings Growth

2019-02-21 08:55:01 | Will Difficult Comparison Hurt Bio-Rad's BIO Q4 Earnings?

2019-02-15 07:30:00 | The typical Facebook employee earns double Silicon Valley's median household income. How 50+ big tech employers compare

2019-02-14 19:28:00 | Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response

2019-02-12 18:31:00 | Bio-Rad to Report Fourth-Quarter and Full-Year 2018 Financial Results Thursday, February 28, 2019

2019-02-08 08:07:03 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.

2019-02-04 07:50:00 | Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International — Future Expectations, Projections Moving into 2019

2019-01-29 10:14:29 | Bio-Rad Laboratories, Inc. NYSE:BIO: A Fundamentally Attractive Investment

2019-01-29 08:07:33 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.

2019-01-22 08:07:14 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.

2019-01-15 07:30:00 | This is how much Apple pays a typical employee — and how that compares to Google, Facebook, Netflix, Microsoft, Box and more

2019-01-09 08:07:29 | See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.

2019-01-03 16:30:00 | Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019

2019-01-03 09:10:02 | Luminex Buys MilliporeSigma's Flow Cytometry Unit for $75M

2019-01-02 18:10:00 | Bio-Rad to Participate at the 37th Annual J.P. Morgan Healthcare Conference on January 8

2018-12-09 03:00:03 | Hedge Funds Are Crazy About Bio-Rad Laboratories, Inc. BIO